Our central purpose is to develop therapies to treat atherosclerosis and promote cardiovascular regeneration. Such work will be performed in collaboration with the Clinical, Translational, Inflammation and Immunobiology Groups within the HRI, drawing upon their expertise in these areas of research.
By reducing atherosclerotic plaque build up, we aim to reduce death and disability associated with heart and lower limb arterial disease. Also, by stimulating the growth of new blood vessels in patients with arterial blockages, our work aims to reduce symptoms associated with insufficient blood supply to the heart and legs.
Every day, 23 Australians die from a heart attack. Every year, roughly 55,000 suffer a life-threatening cardiovascular emergency. Like so many, Greg Bridgman never thought it would happen to him.